---
title: Apixaban versus Aspirin for Embolic Stroke of Undetermined Source
date: '2024-02-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38320511/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240207170748&v=2.18.0
source: heidelberg[Affiliation]
description: Apixaban versus Aspirin for Embolic StrokeIn a trial of 352 patients
  with embolic stroke of undetermined source, 5 mg of apixaban administered twice
  daily was compared with 100 mg of aspirin administered once daily for the prevention
  of recurrent ischemic strokes. At 12 months, 13.6% of patients given apixaban had
  new ischemic lesions on magnetic resonance imaging compared with 16.0% of patients
  given aspirin, and the rates of clinically relevant bleeding were also ...
disable_comments: true
---
Apixaban versus Aspirin for Embolic StrokeIn a trial of 352 patients with embolic stroke of undetermined source, 5 mg of apixaban administered twice daily was compared with 100 mg of aspirin administered once daily for the prevention of recurrent ischemic strokes. At 12 months, 13.6% of patients given apixaban had new ischemic lesions on magnetic resonance imaging compared with 16.0% of patients given aspirin, and the rates of clinically relevant bleeding were also ...